Search

Your search keyword '"Bonavita, Simona"' showing total 298 results

Search Constraints

Start Over You searched for: Author "Bonavita, Simona" Remove constraint Author: "Bonavita, Simona" Search Limiters Full Text Remove constraint Search Limiters: Full Text
298 results on '"Bonavita, Simona"'

Search Results

1. Signs and symptoms of COVID‐19 in patients with multiple sclerosis

2. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

3. The effect of air pollution on COVID‐19 severity in a sample of patients with multiple sclerosis

4. Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 + T-Cell Proliferation in Patients With Multiple Sclerosis

5. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic

6. Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study

7. Sex effects across the lifespan in women with multiple sclerosis

9. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

10. Flexibility of brain dynamics is increased and predicts clinical impairment in relapsing-remitting but not in secondary progressive multiple sclerosis

15. Apparently isolated CNS involvement in Erdheim-Chester disease: Case report

16. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study

20. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

21. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

22. Sexual Dysfunction in People with Multiple Sclerosis: The Role of Disease Severity, Illness Perception, and Depression

23. Epidemiological and Immune Profile Analysis of Italian Subjects with Endometriosis and Multiple Sclerosis

24. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

26. Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

27. Repetitive Transcranial Magnetic Stimulation (rTMS) in Mild Cognitive Impairment: Effects on Cognitive Functions—A Systematic Review.

28. Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence

29. Long-Term Neuromodulatory Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Plasmatic Matrix Metalloproteinases (MMPs) Levels and Visuospatial Abilities in Mild Cognitive Impairment (MCI)

31. Editorial: Disease modifying therapies in multiple sclerosis

32. Telemedicine application to headache: a critical review

35. Repetitive Transcranial Magnetic Stimulation (rTMS) of Dorsolateral Prefrontal Cortex May Influence Semantic Fluency and Functional Connectivity in Fronto-Parietal Network in Mild Cognitive Impairment (MCI)

36. Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study

41. Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail

42. Telemedicine in Parkinson's Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic

43. CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab

44. The structural connectome constrains fast brain dynamics

47. sj-pdf-1-taj-10.1177_20406223211029616 – Supplemental material for Digital work engagement among Italian neurologists

48. sj-pdf-2-taj-10.1177_20406223211029616 – Supplemental material for Digital work engagement among Italian neurologists

50. Public Engagement and Neurology: An Update

Catalog

Books, media, physical & digital resources